The immune system is always on patrol, ridding the body of foreign invaders, such as viruses, bacteria or fungi. White blood cells, such as “T cells,” fight infection and cancer.
Cancer cells however, are not recognized as invaders because they are the body’s own cells that have mutated, so that once-healthy cells no longer behave like normal cells.
Elpis’ proprietary mRNADisTM antibody discovery and mSCAFold™ rational protein engineering platforms enable rapid and robust discovery of epitope specific antibody modules for next generation of bi-specific antibodies, dual targeting and armored CAR-T, and mechanism re-directed immunomodulator proteins.
Elpis has a broad preclinical pipeline addressing clinically validated immunotherapy targets with next generation therapies, as well as novel cancer targets. The Company’s lead immuno-oncology product candidates EPIM-001, a dual functional IL-2Rb agonist with minimal IL-2Ra activation to treat solid tumor indications, EPC-001, a CD19/CD22 dual targeting CAR-T to treat B Cell malignancies are being advanced to enter clinical studies.